Molecular Pharmacology, Physiology, and Structure of the P2Y Receptors

Advances in Pharmacology

Volumn 61, Issue , 2011, Pages 373-415

  von Kugelgen, Ivar ^a   Harden, T Kendall ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

G protein; Nucleotide; P2Y receptor

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CLOPIDOGREL; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; INOSITOL; LIPID; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHOLIPASE C BETA2; PHOSPHOLIPASE C BETA3; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; RHODOPSIN; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

BOOK; DOWNSTREAM PROCESSING; GENETIC ANALYSIS; HUMAN; PHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

EID: 79955961675     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385526-8.00012-6     Document Type: Chapter

References (272)

1. Abbracchio M.P., Burnstock G., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., et al. International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacological Reviews 2006, 58:281-341.
2. Albizu L., Cottet M., Kralikova M., Stoev S., Seyer R., Brabet I., et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nature Chemical Biology 2010, 6:587-594.
3. 12 receptor. Journal of Thrombosis and Haemostasis 2008, 6:1908-1914.
4. 12 locus, is not associated with acute myocardial infarction. PLoS ONE 2008, 3:e1462. 10.1371/journal.pone.0001462.
5. 11 . European Heart Journal 2007, 28:13-18.
6. 12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. Journal of Clinical Investigation 2003, 112:398-406.
7. 12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thrombosis Research 2005, 116:491-497.
8. 1 purinoceptor. Biochemical and Biophysical Research Communications 1996, 218:783-788.
9. o and induce cell migration. Journal of Biological Chemistry 2005, 280:39050-39057.
10. Ballesteros J.A., Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods in Neurosciences 1995, Vol. 25:366-428. Academic Press, USA. P.M. Conn, S.C. Sealfon (Eds.).
11. 12 receptors. Journal of Medicinal Chemistry 2009, 52:3784-3793.
12. Baqi Y., Müller C.E. Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions. Nature Protocols 2010, 5:945-953.
13. 14 receptor-dependent and -independent mechanisms. American Journal of Physiology. Gastrointestinal and Liver Physiology 2009, 296:G923-G930.
14. Bender E., Buist A., Jurzak M., Langlois X., Baggerman G., Verhasselt P., et al. Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8573-8578.
15. 6 receptor. Journal of Medicinal Chemistry 2006, 49:5532-5543.
16. 12 receptor. Molecular Pharmacology 2003, 64:1210-1216.
17. 4 nucleotide receptor. British Journal of Pharmacology 1998, 124:428-430.
18. 12 -ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thrombosis Research 2010, 125:e167-e170.
19. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
20. 12 antagonist cangrelor. Thrombosis and Haemostasis 2010, 103:379-386.
21. 1 receptor antagonist. British Journal of Pharmacology 2002, 135:2004-2010.
22. 2 -purinergic receptor agonists and guanine nucleotides. Journal of Biological Chemistry 1989, 264:884-890.
23. 6 -methyl 2'-deoxyadenosine 3', 5'-bisphosphate. British Journal of Pharmacology 1998, 124:1-3.
24. 1 receptor. Molecular Pharmacology 1996, 50:1323-1329.
25. Boyer J.L., Zohn I.E., Jacobson K.A., Harden T.K. Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. British Journal of Pharmacology 1994, 113:614-620.
26. 4 receptor. Journal of Biological Chemistry 2001, 276:11939-11948.
27. Brunschweiger A., Müller C.E. P2 receptors activated by uracil nucleotides-An update. Current Medicinal Chemistry 2006, 13:289-312.
28. Burnstock G. A. basis for distinguishing two types of purinergic receptor. Cell membrane receptors for drugs and hormones: A multidisciplinary approach 1978, 107-118. Raven Press, USA. R.W. Straub, L. Bolis (Eds.).
29. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiological Reviews 2007, 87:659-797.
30. Burnstock G., Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor?. General Pharmacology 1985, 16:433-440.
31. 2+ influx. Pharmacogenetics and Genomics 2006, 16:199-205.
32. 1 receptors. Journal of Medicinal Chemistry 1998, 41:183-190.
33. 14 receptor. Molecular Pharmacology 2009, 76:1341-1348.
34. 1 receptor. Biochemical Pharmacology 2004, 68:1995-2002.
35. 12 receptor of a patient with congenital bleeding. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:1978-1983.
36. 12 receptor are associated with coronary artery disease. BMC Medical Genetics 2007, 8:59. 10.1186/1471-2350-8-59.
37. Chambers J.K., Macdonald L.E., Sarau H.M., Ames R.S., Freeman K., Foley J.J., et al. A G protein-coupled receptor for UDP-glucose. Journal of Biological Chemistry 2000, 275:10767-10771.
38. Chang K., Hanaoka K., Kumada M., Takuwa Y. Molecular cloning and functional analysis of a novel P2 nucleotide receptor. Journal of Biological Chemistry 1995, 270:26152-26158.
39. Charlton S.J., Brown C.A., Weisman G.A., Turner J.T., Erb L., Boarder M.R. PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors. British Journal of Pharmacology 1996, 118:704-710.
40. 4 receptors: Characterization of a suramin and PPADS-insensitive response to UTP. British Journal of Pharmacology 1996, 119:1301-1303.
41. Charlton M.E., Williams A.S., Fogliano M., Sweetnam P.M., Duman R.S. The isolation and characterization of a novel G protein-coupled receptor regulated by immunologic challenge. Brain Research 1997, 764:141-148.
42. 3 receptors. Science 2006, 314:1792-1795.
43. Chen Z.P., Krull N., Xu S., Levy A., Lightman S.L. Molecular cloning and functional characterization of a rat pituitary G protein-coupled adenosine triphosphate (ATP) receptor. Endocrinology 1996, 137:1833-1840.
44. 2 -adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
45. 13 receptors by conformational constraint of an ADP analog. Journal of Pharmacology and Experimental Therapeutics 2004, 311:1038-1043.
46. 1 receptor: Relationship to internalization and scaffolding. Journal of Biological Chemistry 2008, 283:11050-11063.
47. Communi D., Gonzalez N.S., Detheux M., Brezillon S., Lannoy V., Parmentier M., et al. Identification of a novel human ADP receptor coupled to Gi. Journal of Biological Chemistry 2001, 276:41479-41485.
48. Communi D., Govaerts C., Parmentier M., Boeynaems J.M. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. Journal of Biological Chemistry 1997, 272:31969-31973.
49. 4 receptor. European Journal of Pharmacology 1996, 317:383-389.
50. 6 receptor. Biochemical and Biophysical Research Communications 1996, 222:303-308.
51. Communi D., Pirotton S., Parmentier M., Boeynaems J.M. Cloning and functional expression of a human uridine nucleotide receptor. Journal of Biological Chemistry 1995, 270:30849-30852.
52. 11 receptor. British Journal of Pharmacology 1999, 128:1199-1206.
53. Cooper D.M., Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 1979, 282:517-518.
54. 6 receptor: Molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. Journal of Medicinal Chemistry 2005, 48:8108-8111.
55. Costanzi S., Mamedova L., Gao Z.G., Jacobson K.A. Architecture of P2Y nucleotide receptors: Structural comparison based on sequence analysis, mutagenesis, and homology modeling. Journal of Medicinal Chemistry 2004, 47:5393-5404.
56. 12 receptors. Bioorganic & Medicinal Chemistry 2009, 17:4612-4621.
57. - transport. Journal of Biological Chemistry 1999, 274:26461-26468.
58. 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 2009, 113:4110-4113.
59. 6 receptor architecture in native and transfected neuronal systems. Biochimica et Biophysica Acta 2007, 1768:1592-1599.
60. 14 receptor agonists: Truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. Journal of Medicinal Chemistry 2010, 53:471-480.
61. 1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3', 5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. Bioconjugate Chemistry 2010, 21:1190-1205.
62. Devader C., Drew C.M., Geach T.J., Tabler J., Townsend-Nicholson A., Dale L. A novel nucleotide receptor in Xenopus activates the cAMP second messenger pathway. FEBS Letters 2007, 581:5332-5336.
63. 12 receptor when interacting with antagonists. Journal of Thrombosis and Haemostasis 2009, 7:232-234.
64. 12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003, 101:3908-3914.
65. 12 receptor. Molecular Pharmacology 2006, 69:338-345.
66. q coupling. American Journal of Physiology. Cell Physiology 2005, 288:C559-C567.
67. 12 receptor. Journal of Medicinal Chemistry 2008, 51:1007-1025.
68. Dranoff J.A., O'Neill A.F., Franco A.M., Cai S.Y., Connolly G.C., Ballatori N., et al. A primitive ATP receptor from the little skate Raja erinacea. Journal of Biological Chemistry 2000, 275:30701-30706.
69. Drury A.N., Szent-Györgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. Journal de Physiologie 1929, 68:213-237.
70. 11 nucleotide receptor: Mutational analysis. British Journal of Pharmacology 2008, 155:1250-1255.
71. 11 receptor. Biochemical Journal 2008, 409:107-116.
72. 11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues. British Journal of Pharmacology 2006, 149:416-423.
73. Elliott M.R., Chekeni F.B., Trampont P.C., Lazarowski E.R., Kadl A., Walk S.F., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461:282-286.
74. 12 receptors. Bioorganic & Medicinal Chemistry Letters 2005, 15:5450-5452.
75. 6 receptors. Journal of Medicinal Chemistry 2006, 49:7076-7087.
76. 12 receptor in nucleotide inhibition of exocytosis from bovine chromaffin cells. Molecular Pharmacology 2004, 66:601-611.
77. Erb L., Garrad R., Wang Y., Quinn T., Turner J.T., Weisman G.A. Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. Journal of Biological Chemistry 1995, 270:4185-4188.
78. Erb L., Lustig K.D., Sullivan D.M., Turner J.T., Weisman G.A. Functional expression and photoaffinity labeling of a cloned P2U purinergic receptor. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:10449-10453.
79. 1 -deficient mice. Nature Medicine 1999, 5:1199-1202.
80. 4 receptor to neuronal ion channels. British Journal of Pharmacology 2003, 138:400-406.
81. Filtz T.M., Li Q., Boyer J.L., Nicholas R.A., Harden T.K. Expression of a cloned P2Y purinergic receptor that couples to phospholipase C. Molecular Pharmacology 1994, 46:8-14.
82. 12 gene sequence variations in healthy subjects. Circulation 2003, 108:989-995.
83. 1 gene polymorphism and ADP-induced platelet response. Journal of Thrombosis and Haemostasis 2005, 3:2349-2350.
84. Foster C.J., Prosser D.M., Agans J.M., Zhai Y., Smith M.D., Lachowicz J.E., et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. Journal of Clinical Investigation 2001, 107:1591-1598.
85. Fredriksson R., Lagerstrom M.C., Lundin L.G., Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Molecular Pharmacology 2003, 63:1256-1272.
86. Freeman K., Tsui P., Moore D., Emson P.C., Vawter L., Naheed S., et al. Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs. Genomics 2001, 78:124-128.
87. 14 receptor in model cell systems. Journal of Pharmacology and Experimental Therapeutics 2009, 330:162-168.
88. 14 receptor. Journal of Pharmacology and Experimental Therapeutics 2008, 325:588-594.
89. 13 receptor. Biochemical Pharmacology 2004, 68:113-124.
90. Gachet C. Regulation of platelet functions by P2 receptors. Annual Review of Pharmacology and Toxicology 2006, 46:277-300.
91. 14 receptors is a mediator of mast cell degranulation. Biochemical Pharmacology 2010, 79:873-879.
92. 1 receptor signaling without affecting nucleotide binding. Biochemical Pharmacology 2004, 68:231-237.
93. 4 receptors in the regulation of intestinal chloride secretion. British Journal of Pharmacology 2005, 146:364-369.
94. 6 -receptor agonist. Journal of Medicinal Chemistry 2010, 53:1673-1685.
95. Gorzalka S., Vittori S., Volpini R., Cristalli G., von Kügelgen I., Müller C.E. Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues. Molecular Pharmacology 2005, 67:955-964.
96. 11 receptor. Journal of Medicinal Chemistry 2007, 50:5600-5607.
97. 1 receptor. Drug Develepmont Research 2002, 57:173-181.
98. Haitina T., Fredriksson R., Foord S.M., Schiöth H.B., Gloriam D.E. The G protein-coupled receptor subset of the dog genome is more similar to that in humans than rodents. BMC Genomics 2009, 10:24. 10.1186/1471-2164-10-24.
99. 14 receptor. Acta Physiologica (Oxford) 2010, 199:149-160.
100. Harden T.K., Sondek J. Regulation of phospholipase C isozymes by Ras superfamily GTPases. Annual Review of Pharmacology and Toxicology 2006, 46:355-379.
101. 12 receptors by prasugrel. Biochemical Pharmacology 2007, 74:1003-1009.
102. 12 receptor regulates microglial activation by extracellular nucleotides. Nature Neuroscience 2006, 9:1512-1519.
103. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. British Journal Haematology 1998, 103:858-866.
104. 1 receptor with strong antithrombotic activity in mice. Journal of Pharmacology and Experimental Therapeutics 2006, 316:556-563.
105. 1 receptor: Similarities to the platelet ADP receptor. Molecular Pharmacology 1998, 53:727-733.
106. Henderson D.J., Elliot D.G., Smith G.M., Webb T.E., Dainty I.A. Cloning and characterisation of a bovine P2Y receptor. Biochemical and Biophysical Research Communications 1995, 212:648-656.
107. Hepler J.R., Gilman A.G. G proteins. Trends in Biochemical Science 1992, 17:383-387.
108. Herbert J.M., Tissinier A., Defreyn G., Maffrand J.P. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arteriosclerosis and Thrombosis 1993, 13:1171-1179.
109. 4 receptor is determined by the second extracellular loop. Journal of Biological Chemistry 2004, 279:11456-11464.
110. 1 ADP receptor gene is associated with increased platelet activation response to ADP. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:252-257.
111. 2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. Journal of Medicinal Chemistry 2009, 52:2762-2775.
112. 2 receptor in bone remodeling. Journal of Cellular Biochemistry 2002, 86:413-419.
113. 12 receptor. Journal of Pharmacology and Experimental Therapeutics 2009, 331:648-655.
114. 1 receptor in surface expression and activation processes. Journal of Biological Chemistry 1999, 274:14639-14647.
115. 12 -receptor. Biochemical Pharmacology 2008, 76:1201-1213.
116. 1/6 chimeric receptors. Biochemical Pharmacology 2004, 68:2075-2086.
117. Hoffmann C., Ziegler N., Reiner S., Krasel C., Lohse M.J. Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and -2. Journal of Biological Chemistry 2008, 283:30933-30941.
118. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409:202-207.
119. 6 receptors. American Journal of Physiology. Heart and Circulatory Physiology 2002, 282:H784-H792.
120. 1 receptors. British Journal of Pharmacology 2006, 147:459-467.
121. Ingall A.H., Dixon J., Bailey A., Coombs M.E., Cox D., McInally J.I., et al. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy. Journal of Medicinal Chemistry 1999, 42:213-220.
122. 14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. Bioorganic & Medicinal Chemistry Letters 2007, 17:761-766.
123. 2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. Journal of Medicinal Chemistry 2007, 50:1166-1176.
124. 2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
125. Jacobson K.A. GPCR ligand-dendrimer (GLiDe) conjugates: Future smart drugs?. Trends in Pharmacological Sciences 2010, 31:575-579.
126. 4 receptors. Biochemical Pharmacology 2006, 71:540-549.
127. Jacobson K.A., Ivanov A.A., de Castro S., Harden T.K., Ko H. Development of selective agonists and antagonists of P2Y receptors. Purinergic Signalling 2009, 5:75-89.
128. Jacobson K.A., Mamedova L., Joshi B.V., Besada P., Costanzi S. Molecular recognition at adenine nucleotide (P2) receptors in platelets. Seminars in Thrombosis and Hemostasis 2005, 31:205-216.
129. 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal 2009, 157:599-605.
130. 1 receptor. Biochemical and Biophysical Research Communications 1996, 221:588-593.
131. 2 receptor polymorphism: Identification and pharmacological characterization of two allelic variants. British Journal of Pharmacology 1999, 127:709-716.
132. i2 . Journal of Clinical Investigation 2001, 108:477-483.
133. 1 receptor. Molecular Pharmacology 1997, 52:499-507.
134. 1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. Journal of Biological Chemistry 1998, 273:2030-2034.
135. 12 ADP-receptor antagonist, INS50589. Platelets 2007, 18:346-356.
136. Kauffenstein G., Hechler B., Cazenave J.P., Gachet C. Adenine triphosphate nucleotides are antagonists at the P2Y receptor. Journal of Thrombosis and Haemostasis 2004, 2:1980-1988.
137. 4 receptor. Molecular Pharmacology 2000, 57:926-931.
138. 13 receptor. Biochemical Pharmacology 2005, 70:266-274.
139. 1 receptor antagonists. Journal of Medicinal Chemistry 2003, 46:4974-4987.
140. 6 receptor agonists. Bioorganic & Medicinal Chemistry 2008, 16:6319-6332.
141. 14 receptor. Journal of Medicinal Chemistry 2007, 50:2030-2039.
142. 6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. Journal of Biological Chemistry 2005, 280:16909-16915.
143. Lagerström M.C., Schiöth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Reviews. Drug Discovery 2008, 7:339-357.
144. 1 receptor supports leptin secretion in adipose tissue. Endocrinology 2010, 151:2060-2070.
145. Lazarowski E.R., Homolya L., Boucher R.C., Harden T.K. Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. Journal of Biological Chemistry 1997, 272:24348-24354.
146. Lazarowski E.R., Rochelle L.G., O'Neal W.K., Ribeiro C.M., Grubb B.R., Zhang V., et al. Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder. Journal of Pharmacology and Experimental Therapeutics 2001, 297:43-49.
147. Lazarowski E.R., Watt W.C., Stutts M.J., Boucher R.C., Harden T.K. Pharmacological selectivity of the cloned human P2U-purinoceptor: Potent activation by diadenosine tetraphosphate. British Journal of Pharmacology 1995, 116:1619-1627.
148. Leipziger J. Control of epithelial transport via luminal P2 receptors. American Journal of Physiology - Renal Physiology 2003, 284:F419-F432.
149. 1 receptor-null mice. Journal of Clinical Investigation 1999, 104:1731-1737.
150. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Letters 1997, 403:26-30.
151. 1 purinoceptor. Gene 1996, 171:295-297.
152. 6 receptor. Molecular Pharmacology 1998, 54:541-546.
153. Li Q., Schachter J.B., Harden T.K., Nicholas R.A. The 6H1 orphan receptor, claimed to be the p2y5 receptor, does not mediate nucleotide-promoted second messenger responses. Biochemical and Biophysical Research Communications 1997, 236:455-460.
154. Lustig K.D., Shiau A.K., Brake A.J., Julius D. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:5113-5117.
155. Lutz S., Freichel-Blomquiest A., Yang Y., Rumenapp U., Jakobs K.H., Schmidt M., Wieland T. The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and Rho. Journal of Biological Chemistry 2005, 280:1134-1139.
156. Maffrand J.P., Bernat A., Delebassee D., Defreyn G., Cazenave J.P., Gordon J.L. ADP plays a key role in thrombogenesis in rats. Thrombosis and Haemostasis 1988, 59:225-230.
157. 6 cDNAs and identification of a pseudogene: Comparison of P2Y receptor subtype expression in bone and brain tissues. Biochemical and Biophysical Research Communications 1997, 240:298-302.
158. 1 -receptor. Journal of Medicinal Chemistry 2004, 47:4391-4404.
159. 1 -receptor. Journal of Medicinal Chemistry 2004, 47:4405-4416.
160. Malin S.A., Molliver D.C. Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. Molecular Pain 2009, 6:21.
161. 6 receptor mediated contractions in human cerebral arteries. BMC Pharmacology 2003, 3:4. 10.1186/1471-2210-3-4.
162. 6 nucleotide receptors. Biochemical Pharmacology 2004, 67:1763-1770.
163. 12 receptor. European Journal of Pharmacology 2010, 644:10-16.
164. 13 receptor. Molecular Pharmacology 2003, 64:104-112.
165. 6 receptor agonists: Novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. Journal of Medicinal Chemistry 2010, 53:4488-4501.
166. Meis S., Hamacher A., Hongwiset D., Marzian C., Wiese M., Eckstein N., et al. NF546 [4, 4'-(carbonylbis(imino-3, 1-phenylene-carbonylimino-3, 1-(4-methyl-phenylene)-carbonylimino))-bis(1, 3-xylene-alpha, alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. Journal of Pharmacology and Experimental Therapeutics 2010, 332:238-247.
167. Milligan G. G protein-coupled receptor hetero-dimerization: Contribution to pharmacology and function. British Journal of Pharmacology 2009, 158:5-14.
168. 1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2008, 18:6222-6226.
169. 11 purinergic receptor. Cell Calcium 2008, 43:344-355.
170. 11 purinergic receptor in human granulocytes. Journal of Biological Chemistry 2006, 281:31419-31429.
171. 1 receptor: Molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. Journal of Medicinal Chemistry 1998, 41:1456-1466.
172. 1 receptor. Biochemistry 1999, 38:3498-3507.
173. Morris G.E., Nelson C.P., Everitt D., Brighton P.J., Standen N.B., Challiss R.A., et al. G protein-coupled receptor kinase 2 and arrestin2 regulate arterial smooth muscle P2Y-purinoceptor signalling. Cardiovascular Research 2010, in press.
174. Müller C.E. P2-pyrimidinergic receptors and their ligands. Current Pharmaceutical Design 2002, 8:2353-2369.
175. 1 receptor ligands. Journal of Medicinal Chemistry 2000, 43:829-842.
176. Nguyen T., Erb L., Weisman G.A., Marchese A., Heng H.H., Garrad R.C., et al. Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene. Journal of Biological Chemistry 1995, 270:30845-30848.
177. Nicholas R.A., Watt W.C., Lazarowski E.R., Li Q., Harden K. Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: Identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Molecular Pharmacology 1996, 50:224-229.
178. 12 receptor antagonist activity. Seminars in Thrombosis and Hemostasis 2005, 31:184-194.
179. Noguchi K., Ishii S., Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. Journal of Biological Chemistry 2003, 278:25600-25606.
180. 2 receptor through an epidermal growth factor receptor-transregulated mechanism. Journal of Biological Chemistry 2010, 285:2940-2950.
181. North R.A. Molecular physiology of P2X receptors. Physiological Reviews 2002, 82:1013-1067.
182. 1 receptor expression in Xenopus oocytes. Journal of Biological Chemistry 1996, 271:29080-29087.
183. 125 I]MRS2500). Pharmacological Research 2010, 62:344-351.
184. 1 receptor. Molecular Pharmacology 1998, 54:1118-1123.
185. Park J.H., Scheerer P., Hofmann K.P., Choe H.W., Ernst O.P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008, 454:183-187.
186. 12 antagonists for inhibition of platelet aggregation. Journal of Medicinal Chemistry 2010, 53:2010-2037.
187. 12 antagonists for inhibition of platelet aggregation. Bioorganic & Medicinal Chemistry Letters 2009, 19:4657-4663.
188. Parr C.E., Sullivan D.M., Paradiso A.M., Lazarowski E.R., Burch L.H., Olsen J.C., et al. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:3275-3279.
189. Pasternack S.M., von Kügelgen I., Aboud K.A., Lee Y.A., Rüschendorf F., Voss K., et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nature Genetics 2008, 40:329-334.
190. Patel K., Barnes A., Camacho J., Paterson C., Boughtflower R., Cousens D., et al. Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. European Journal of Pharmacology 2001, 430:203-210.
191. 12 receptors in Saccharomyces cerevisiae. Biochemical and Biophysical Research Communications 2004, 324:171-177.
192. Pendergast W., Yerxa B.R., Douglass J.G., Shaver S.R., Dougherty R.W., Redick C.C., et al. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. Bioorganic & Medicinal Chemistry Letters 2001, 11:157-160.
193. 1 receptor antagonists as novel antithrombotic agents. Bioorganic & Medicinal Chemistry Letters 2008, 18:3338-3343.
194. 11 receptor to phospholipase C and adenylyl cyclase. British Journal of Pharmacology 2001, 132:318-326.
195. 2 receptor is located in its first extracellular loop. Journal of Biological Chemistry 2005, 280:29169-29175.
196. 11 receptors. Molecular Pharmacology 2001, 60:1375-1382.
197. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacological Reviews 1998, 50:413-492.
198. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450:383-387.
199. 1 receptor are dependent on C-terminal phosphorylation sites. Molecular Pharmacology 2009, 76:1162-1171.
200. 12 of a patient with haemorrhagic diathesis. Clinical Chemistry and Laboratory Medicine 2007, 45:187-189.
201. Rice W.R., Burton F.M., Fiedeldey D.T. Cloning and expression of the alveolar type II cell P2u-purinergic receptor. American Journal of Respiratory Cell and Molecular Biology 1995, 12:27-32.
202. 6 receptor. European Journal of Pharmacology 1997, 329:231-236.
203. 4 -null mice. Molecular Pharmacology 2003, 63:777-783.
204. 12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circulation. Cardiovascular Genetics 2009, 2:515-521.
205. 2 receptor antagonists. Bioorganic & Medicinal Chemistry 2009, 17:5071-5079.
206. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Hemostasis 2005, 31:174-183.
207. 12 , a new platelet ADP receptor, target of clopidogrel. Biochemical and Biophysical Research Communications 2001, 283:379-383.
208. 12 receptor oligomers and partitions them out of lipid rafts. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:11069-11074.
209. 1 -purinoceptor. British Journal of Pharmacology 1996, 118:167-173.
210. 12 haplotype and risk of cardiovascular events in chronic coronary disease. Thrombosis Research 2006, 118:679-683.
211. 12 -like receptor group. Purinergic Signalling 2007, 3:255-268.
212. Seifert R., Schultz G. Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides. Trends in Pharmacological Sciences 1989, 10:365-369.
213. Shaver S.R., Rideout J.L., Pendergast W., Douglass J.G., Brown E.G., Boyer J.L., et al. Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. Purinergic Signalling 2005, 1:183-191.
214. 2 receptor in coronary artery smooth muscle cells. Molecular Pharmacology 2004, 66:1265-1274.
215. 12 deficiency caused by a mutation in the translation initiation codon. Journal of Thrombosis and Haemostasis 2005, 3:2315-2323.
216. T -type receptor in brain capillary endothelial cells. British Journal of Pharmacology 2001, 132:173-182.
217. Smrcka A.V. G protein betagamma subunits: Central mediators of G protein-coupled receptor signaling. Cellular and Molecular Life Sciences 2008, 65:2191-2214.
218. Southey M.C., Hammet F., Hutchins A.M., Paidhungat M., Somers G.R., Venter D.J. Molecular cloning and sequencing of a novel human P2 nucleotide receptor. Biochimica et Biophysica Acta 1996, 1309:77-80.
219. 12 receptor antagonist for the prevention of thrombosis. Bioorganic & Medicinal Chemistry Letters 2007, 17:6013-6018.
220. 12 -ADP receptor gene. International Journal of Cardiology 2009, 133:341-345.
221. 1 , and ITGB3. Platelets 2009, 20:341-348.
222. 4 nucleotide receptor. European Journal of Pharmacology 2001, 416:197-202.
223. Sugidachi A., Asai F., Ogawa T., Inoue T., Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology 2000, 129:1439-1446.
224. 2 receptor. Biochemical and Biophysical Research Communications 2006, 351:559-565.
225. 1 receptor. Molecular Pharmacology 2001, 60:432-439.
226. Tauber J., Davitt W.F., Bokosky J.E., Nichols K.K., Yerxa B.R., Schaberg A.E., et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004, 23:784-792.
227. Tokuyama Y., Hara M., Jones E.M., Fan Z., Bell G.I. Cloning of rat and mouse P2Y purinoceptors. Biochemical and Biophysical Research Communications 1995, 211:211-218.
228. 11 receptors activate adenylyl cyclase and contribute to nucleotide-promoted cAMP formation in MDCK-D1 cells. A mechanism for nucleotide-mediated autocrine-paracrine regulation. Journal of Biological Chemistry 2002, 277:7761-7765.
229. 11 receptor antagonists with nanomolar potency. Journal of Medicinal Chemistry 2005, 48:7040-7048.
230. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. Journal of Thrombosis and Haemostasis 2009, 7:1556-1565.
231. van Rhee A.M., Fischer B., van Galen P.J., Jacobson K.A. Modelling the P2Y purinoceptor using rhodopsin as template. Drug Design & Discovery 1995, 13:133-154.
232. 12 . Neuropharmacology 2003, 45:145-154.
233. von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacology & Therapeutics 2006, 110:415-432.
234. von Kügelgen I., Häussinger D., Starke K. Evidence for a vasoconstriction-mediating receptor for UTP, distinct from the P2 purinoceptor, in rabbit ear artery. Naunyn-Schmiedeberg's Archives of Pharmacology 1987, 336:556-560.
235. i protein-coupled receptor for adenine from mouse brain. Molecular Pharmacology 2008, 73:469-477.
236. 1 -receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 1992, 346:187-196.
237. von Kügelgen I., Wetter A. Molecular pharmacology of P2Y-receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 2000, 362:310-323.
238. 1 receptor with a high affinity radiolabeled antagonist. Molecular Pharmacology 2002, 62:1249-1257.
239. 1 receptor. Molecular Pharmacology 2004, 65:426-436.
240. 2 ) gene with myocardial infarction in Japanese men. Circulation Journal 2009, 73:2322-2329.
241. 2 ) gene associated with essential hypertension in Japanese men. Journal of Human Hypertension 2010, 24:327-335.
242. 2 ) gene is associated with cerebral infarction in Japanese subjects. Hypertension Research 2009, 32:989-996.
243. 12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thrombosis and Haemostasis 2007, 97:847-855.
244. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454:486-491.
245. 6 nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. Journal of Biological Chemistry 2001, 276:26051-26056.
246. 2 and GPVI receptors. Hämostaseologie 2010, 30:29-38.
247. 3 ) activated preferentially by nucleoside diphosphates. Molecular Pharmacology 1996, 50:258-265.
248. 4 receptor. Journal of Neurochemistry 1998, 71:1348-1357.
249. Webb T.E., Simon J., Krishek B.J., Bateson A.N., Smart T.G., King B.F., et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Letters 1993, 324:219-225.
250. 2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2008, 18:223-227.
251. 11 receptors: Evidence for agonist-specific signaling. Molecular Pharmacology 2003, 63:1356-1363.
252. 2+ ions. British Journal of Pharmacology 2003, 140:1177-1186.
253. 11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. Journal of Immunology 2001, 166:7172-7177.
254. 13 receptor-type. British Journal of Pharmacology 2004, 141:141-151.
255. Wolff S.C., Qi A.D., Harden T.K., Nicholas R.A. Polarized expression of human P2Y receptors in epithelial cells from kidney, lung, and colon. American Journal of Physiology. Cell Physiology 2005, 288:C624-C632.
256. 1 receptor constitute a basolateral-sorting signal. Journal of Cell Science 2010, 123:2512-2520.
257. Xu B., Stephens A., Kirschenheuter G., Greslin A.F., Cheng X., Sennelo J., et al. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: Phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. Journal of Medicinal Chemistry 2002, 45:5694-5709.
258. Yanagida K., Masago K., Nakanishi H., Kihara Y., Hamano F., Tajima Y., et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. Journal of Biological Chemistry 2009, 284:17731-17741.
259. 12 on human platelets. ChemMedChem 2008, 3:732-736.
260. Yerxa B.R. Therapeutic use of nucleotides in respiratory and ophthalmic diseases. Drug Development Research 2001, 52:196-201.
261. 2 receptor agonist for the treatment of cystic fibrosis. Journal of Pharmacology and Experimental Therapeutics 2002, 302:871-880.
262. Yokomizo T., Izumi T., Chang K., Takuwa Y., Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620-624.
263. Yoshioka K., Saitoh O., Nakata H. Heteromeric association creates a P2Y-like adenosine receptor. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:7617-7622.
264. 1 receptors in living cells. FEBS Letters 2002, 523:147-151.
265. 11 receptors in Madin Darby canine kidney cells. Molecular Pharmacology 2001, 60:26-35.
266. 2 receptor of MDCK cells: Cloning, expression, and cell-specific signaling. American Journal of Physiology. Renal Physiology 2000, 279:F1045-F1052.
267. Zee R.Y., Michaud S.E., Diehl K.A., Chasman D.I., Emmerich J., Gaussem P., et al. Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. Atherosclerosis 2008, 197:694-699.
268. 12 antagonism. Thrombosis and Haemostasis 2010, 104:845-857.
269. Zhang F.L., Luo L., Gustafson E., Lachowicz J., Smith M., Qiao X., et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. Journal of Biological Chemistry 2001, 276:8608-8615.
270. i -coupled ADP receptor from human and mouse. Journal of Pharmacology and Experimental Therapeutics 2002, 301:705-713.
271. 12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression. FEBS Letters 2004, 562:111-117.
272. 11 nucleotide receptor deduced from computational modelling and mutational analysis. Biochemical Journal 2007, 405:277-286.